Biomedical manufacturing cushions Singapore’s monthly factory production

Singapore's skyline

Singapore’s monthly factory output numbers--a bellwether for the region’s economic health--got a big boost from the biomedical manufacturing sector.

Although factory output dipped 0.5% in March when compared to the same month a year ago, a 23.1% increase in biomedical production kept the overall number from hitting the 2% analysts had forecast, The Straits Times of Singapore reported.

Excluding output from the sometimes unpredictable biomedical sector, total output fell 5.5%, according to data from the country’s Economic Development Board released this week.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The pharmaceutical industry provided the biggest push within the biomedical sector, surging 27.9% in March. However, analysts cautioned that pharma manufacturing is prone to month-to-month peaks and valleys depending on where they are in the drug production cycle.

“Most drugmakers produce active pharmaceutical ingredients (APIs), and can churn out only one batch of APIs at a time,”  Irvin Seah, an economist, told the publication. “When they change their product mix, they have to shut down their plants for sterilization for about a month.”

Still, API orders tend to be very large so when the plants are running, they do so at full capacity, Seah added.

Total factory output has declined for 12 of the past 13 months, seeing only a 1.1% year-on-year gain in January.

- here’s The Straits Times story

Related Articles:
Parexel opens Singapore distribution facility


Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.